| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 抗炎类(元) | - | - | 176,250,429.11 |
| 抗肿瘤类(元) | 16,419,201.42 | 23,617,795.53 | 11,508,623.40 |
| 心血管类(元) | 37,760,622.99 | 63,491,813.84 | 32,959,160.08 |
| 非甾体抗炎类(元) | 159,778,817.35 | 317,240,874.75 | - |
| 其他(元) | 20,809,706.17 | 41,513,847.19 | 21,148,742.52 |
| 营业成本(元) | |||
| 抗炎类(元) | - | - | 127,163,609.65 |
| 抗肿瘤类(元) | 18,277,201.81 | 17,893,965.51 | 8,714,623.79 |
| 心血管类(元) | 10,635,645.82 | 13,225,095.75 | 7,567,770.89 |
| 非甾体抗炎类(元) | 135,381,420.21 | 259,146,753.06 | - |
| 其他(元) | 19,053,451.18 | 27,007,736.73 | 11,340,684.27 |
| 毛利(元) | |||
| 抗炎类(元) | - | - | 49,086,819.46 |
| 抗肿瘤类(元) | -1,858,000.39 | 5,723,830.02 | 2,793,999.61 |
| 心血管类(元) | 27,124,977.17 | 50,266,718.09 | 25,391,389.19 |
| 非甾体抗炎类(元) | 24,397,397.14 | 58,094,121.69 | - |
| 其他(元) | 1,756,254.99 | 14,506,110.46 | 9,808,058.25 |
| 毛利率(%) | |||
| 抗炎类(%) | - | - | 27.85 |
| 抗肿瘤类(%) | -11.32 | 24.24 | 24.28 |
| 心血管类(%) | 71.83 | 79.17 | 77.04 |
| 非甾体抗炎类(%) | 15.27 | 18.31 | - |
| 其他(%) | 8.44 | 34.94 | 46.38 |
| 收入构成(%) | |||
| 抗炎类(%) | - | - | 72.87 |
| 抗肿瘤类(%) | 6.99 | 5.30 | 4.76 |
| 心血管类(%) | 16.08 | 14.24 | 13.63 |
| 非甾体抗炎类(%) | 68.06 | 71.15 | - |
| 其他(%) | 8.86 | 9.31 | 8.74 |
| 毛利构成(%) | |||
| 抗炎类(%) | - | - | 56.37 |
| 抗肿瘤类(%) | -3.61 | 4.45 | 3.21 |
| 心血管类(%) | 52.75 | 39.09 | 29.16 |
| 非甾体抗炎类(%) | 47.45 | 45.18 | - |
| 其他(%) | 3.42 | 11.28 | 11.26 |